Premium
Cardiac Amyloidosis as a Potential Risk Factor for Transapical Transcatheter Aortic Valve Implantation
Author(s) -
Monticelli Fabio C.,
Kunz Sebastian N.,
Keller Thomas,
Bleiziffer Sabine
Publication year - 2014
Publication title -
journal of cardiac surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 58
eISSN - 1540-8191
pISSN - 0886-0440
DOI - 10.1111/jocs.12305
Subject(s) - medicine , stenosis , amyloidosis , cardiology , cardiac amyloidosis , prosthesis , aortic valve , risk factor , aortic valve stenosis , cardiac catheterization , surgery , prosthesis implantation
Transcatheter aortic valve implantation via transarterial or transapical access is an alternative therapy to treat high‐risk patients with severe symptomatic aortic stenosis. Despite growing experience, procedural complications may still occur. We herein report an 86‐year‐old female patient with fatal left ventricular rupture after transapical transcatheter aortic valve implantation with an Edwards Sapien prosthesis due to severe cardiac amyloidosis. doi: 10.1111/jocs.12305 (J Card Surg 2014;29:623–624)